118 related articles for article (PubMed ID: 20840811)
1. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing gene 1 in lung cancer cell A549/DDP].
Gao Y; Su D; Ying L; Lv W; Ma S
Zhongguo Fei Ai Za Zhi; 2010 Sep; 13(9):846-9. PubMed ID: 20840811
[TBL] [Abstract][Full Text] [Related]
2. [RNA interference silencing excision repair cross-complementing 1 gene and affecting cisplatin sensitivity on lung cancer cell lines].
Shang XB; Yu ZT; Tang P; Zhang XZ
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2799-802. PubMed ID: 19080461
[TBL] [Abstract][Full Text] [Related]
3. [Enhanced cisplatin cytotoxicity by RNA interfering the excision repair cross-complementing 1 gene in ovarian cancer cell lines].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):339-42. PubMed ID: 16762192
[TBL] [Abstract][Full Text] [Related]
4. ERCC1 siRNA ameliorates drug resistance to cisplatin in gastric carcinoma cell lines.
Li W; Jie Z; Li Z; Liu Y; Gan Q; Mao Y; Wang X
Mol Med Rep; 2014 Jun; 9(6):2423-8. PubMed ID: 24699918
[TBL] [Abstract][Full Text] [Related]
5. Lentivirus-Mediated RNAi silencing targeting ERCC1 reverses cisplatin resistance in cisplatin-resistant ovarian carcinoma cell line.
Du P; Zhang X; Liu H; Chen L
DNA Cell Biol; 2015 Jul; 34(7):497-502. PubMed ID: 25941922
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between nucleotide excision repair gene ERCC1 and resistance to cisplatin in ovarian cancer].
Liu GY; Qu QX; Mi RR; Qi J
Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):184-7. PubMed ID: 18756932
[TBL] [Abstract][Full Text] [Related]
7. DNA Repair Genes ERCC1 and BRCA1 Expression in Non-Small Cell Lung Cancer Chemotherapy Drug Resistance.
Wang S; Liu F; Zhu J; Chen P; Liu H; Liu Q; Han J
Med Sci Monit; 2016 Jun; 22():1999-2005. PubMed ID: 27289442
[TBL] [Abstract][Full Text] [Related]
8. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.
Chang IY; Kim MH; Kim HB; Lee DY; Kim SH; Kim HY; You HJ
Biochem Biophys Res Commun; 2005 Feb; 327(1):225-33. PubMed ID: 15629453
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of p38 MAPK-dependent excision repair cross-complementing 1 expression decreases the DNA repair capacity to sensitize lung cancer cells to etoposide.
Tsai MS; Weng SH; Chen HJ; Chiu YF; Huang YC; Tseng SC; Kuo YH; Lin YW
Mol Cancer Ther; 2012 Mar; 11(3):561-71. PubMed ID: 22053010
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.
Cheng H; Zhang Z; Borczuk A; Powell CA; Balajee AS; Lieberman HB; Halmos B
Carcinogenesis; 2013 Apr; 34(4):739-49. PubMed ID: 23275151
[TBL] [Abstract][Full Text] [Related]
11. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
12. [Effect of XPG down-regulation gene expression towards the proliferation of epithelial ovarian cancer cells and its chemosensitivity to platinum].
Zhang W; Wu FX; Wang Q; Li L
Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):286-91. PubMed ID: 22781116
[TBL] [Abstract][Full Text] [Related]
13. [Effect of Peimine on ERCC1 mRNA and LRP Expressions of A549/DDP Multidrug Resistance Cell Line].
Tang XY; Tang YX; Xu P; Zhou HY; Han L
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Dec; 35(12):1490-4. PubMed ID: 26882613
[TBL] [Abstract][Full Text] [Related]
14. Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2.
Ko JC; Su YJ; Lin ST; Jhan JY; Ciou SC; Cheng CM; Chiu YF; Kuo YH; Tsai MS; Lin YW
Lung Cancer; 2010 Aug; 69(2):155-64. PubMed ID: 19962780
[TBL] [Abstract][Full Text] [Related]
15. miR‑138‑5p modulates the expression of excision repair cross‑complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin.
Ning J; Jiao Y; Xie X; Deng X; Zhang Y; Yang Y; Zhao C; Wang H; Gu K
Oncol Rep; 2019 Feb; 41(2):1131-1139. PubMed ID: 30535472
[TBL] [Abstract][Full Text] [Related]
16. The overexpression of ERCC-1 is involved in the resistance of lung cancer cells to cetuximab combined with DDP.
Li JJ; Ding Y; Li DD; Peng RQ; Feng GK; Zeng YX; Zhu XF; Zhang XS
Cancer Biol Ther; 2009 Oct; 8(20):1914-21. PubMed ID: 20009541
[TBL] [Abstract][Full Text] [Related]
17. Integrative PDGF/PDGFR and focal adhesion pathways are downregulated in ERCC1-defective non-small cell lung cancer undergoing sodium glycididazole-sensitized cisplatin treatment.
He L; Wang X; Liu K; Wu X; Yang X; Song G; Zhang B; Zhong L
Gene; 2019 Apr; 691():70-76. PubMed ID: 30584903
[TBL] [Abstract][Full Text] [Related]
18. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Cobo M; Isla D; Massuti B; Montes A; Sanchez JM; Provencio M; Viñolas N; Paz-Ares L; Lopez-Vivanco G; Muñoz MA; Felip E; Alberola V; Camps C; Domine M; Sanchez JJ; Sanchez-Ronco M; Danenberg K; Taron M; Gandara D; Rosell R
J Clin Oncol; 2007 Jul; 25(19):2747-54. PubMed ID: 17602080
[TBL] [Abstract][Full Text] [Related]
19. NDRG1 disruption alleviates cisplatin/sodium glycididazole-induced DNA damage response and apoptosis in ERCC1-defective lung cancer cells.
He L; Liu K; Wang X; Chen H; Zhou J; Wu X; Liu T; Yang Y; Yang X; Cui D; Song G; Wang J; Lei J
Int J Biochem Cell Biol; 2018 Jul; 100():54-60. PubMed ID: 29768183
[TBL] [Abstract][Full Text] [Related]
20. Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer.
Wang S; Pan H; Liu D; Mao N; Zuo C; Li L; Xie T; Huang D; Huang Y; Pan Q; Yang L; Wu J
Int J Oncol; 2015 Feb; 46(2):809-17. PubMed ID: 25434755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]